Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjgren's syndrome: findings in humans and mice
The claim that "over 75% of patients achieve significant pain relief without surgery" with peptide therapy comes from clinical observations, not controlled trials
Conversely, no weight loss drug use was associated with an increased risk at five years (RR, 2.96), seven years (RR, 4.02) and 10 years (RR, 4.30) compared with GLP-1 agonist use
As a result, our patients naturally feel fuller for much longer periods, effortlessly reducing their daily caloric intake without experiencing the intense starvation cravings associated with traditional diets
doi: 10.1177/11782218221118462 10 CarisLBeckersT
Thats roughly 4% of the 3,866 calls related to all GLP-1 medications in that time frame, but its up from the 32 compounded GLP-1 exposure calls in all of 2023